Topping estimates on Wall Street, Abbott (NYSE:ABT) shares climbed yesterday with its second-quarter financial results. Driving the company’s growth was, in part, its diabetes business unit – sales jumped nearly 40% compared to Q2 in 2017 thanks largely to its sensor-based glucose monitoring system, Freestyle Libre.
“Libre offers a true mass-market opportunity with its unique combination of affordability, accessibility and ease of use and it’s achieving a level of patient adoption that’s unprecedented in the industry with more than 800,000 current users globally,” CEO Miles White said in a call with analysts.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott CEO aims for more than one million Libre users by 2019 appeared first on MassDevice.
from MassDevice https://ift.tt/2uNIlkJ
Cap comentari:
Publica un comentari a l'entrada